Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Nov;20(5):583–586. doi: 10.1128/aac.20.5.583

Intraventricular levels of amikacin after intravenous administration.

R Yogev, W M Kolling
PMCID: PMC181755  PMID: 7325626

Abstract

Serum and ventricular fluid pharmacokinetic data for amikacin were evaluated prospectively in 10 hydrocephalic children with suspected ventriculitis. After the fourth or fifth intravenous 7.5-mg/kg dose of amikacin given every 8 h, mean peak serum levels were 24.3 +/- 3.2 microgram/ml (achieved at 0.5 h) with a calculated half-life of 2.2 +/- 1.1 h. Mean peak ventricular fluid levels in five patients with bacterial infection were 6.1 +/- 2.0 microgram/ml (achieved at 3 h). In the remaining five patients without bacterial ventriculitis, very low levels (less than or equal to 0.7 microgram/ml) of amikacin were detected. Ventricular fluid pleocytosis was directly correlated and glucose levels were inversely correlated with penetration of amikacin. Systemic therapy with amikacin may be the treatment of choice for children with ventriculitis meningitis caused by bacteria which are highly susceptible to this drug, thereby permitting the avoidance of the potentially hazardous intraventricular route of administration.

Full text

PDF
583

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acar J. F., Witchitz J. L., Goldstein F., Talbot J. N., Le Goffic F. Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns. J Infect Dis. 1976 Nov;134(Suppl):S280–S285. doi: 10.1093/infdis/135.supplement_2.s280. [DOI] [PubMed] [Google Scholar]
  2. Briedis D. J., Robson H. G. Cerebrospinal fluid penetration of amikacin. Antimicrob Agents Chemother. 1978 Jun;13(6):1042–1043. doi: 10.1128/aac.13.6.1042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chang M. J., Escobedo M., Anderson D. C., Hillman L., Feigin R. D. Kanamycin and gentamicin treatment of neonatal sepsis and meningitis. Pediatrics. 1975 Nov;56(5):695–699. [PubMed] [Google Scholar]
  4. Finland M., Garner C., Wilcox C., Sabath L. D. Susceptibility of recently isolated bacteria to amikacin in vitro: comparisons with four other aminoglycoside antibiotics. J Infect Dis. 1976 Nov;134(Suppl):S297–S307. doi: 10.1093/infdis/135.supplement_2.s297. [DOI] [PubMed] [Google Scholar]
  5. Hodges G. R., Watanabe I., Singer P., Rengachary S., Reeves D., Jusetesen D. R., Worley S. E., Gephardt E. P., Jr Central nervous system toxicity of intraventricularly administered gentamicin in adult rabbits. J Infect Dis. 1981 Feb;143(2):148–155. doi: 10.1093/infdis/143.2.148. [DOI] [PubMed] [Google Scholar]
  6. Kaiser A. B., McGee Z. A. Aminoglycoside therapy of gram-negative bacillary meningitis. N Engl J Med. 1975 Dec 11;293(24):1215–1220. doi: 10.1056/NEJM197512112932401. [DOI] [PubMed] [Google Scholar]
  7. Lambert H. P. Problems with neonatal meningitis. J Antimicrob Chemother. 1977 Sep;3(5):381–382. doi: 10.1093/jac/3.5.381. [DOI] [PubMed] [Google Scholar]
  8. Lewis J. E., Nelson J. C., Elder H. A. Amikacin: a rapid and sensitive radioimmunoassay. Antimicrob Agents Chemother. 1975 Jan;7(1):42–45. doi: 10.1128/aac.7.1.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. McCracken G. H., Jr, Chrane D. F., Thomas M. L. Pharmacologic evaluation of gentamicin in newborn infants. J Infect Dis. 1971 Dec;124 (Suppl):S214–23. doi: 10.1093/infdis/124.supplement_1.s214. [DOI] [PubMed] [Google Scholar]
  10. McCracken G. H., Jr, Mize S. G., Threlkeld N. Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. Lancet. 1980 Apr 12;1(8172):787–791. [PubMed] [Google Scholar]
  11. Mori K., Raimondi A. J. An analysis of external ventricular drainage as a treatment for infected shunts. Childs Brain. 1975;1(4):243–250. doi: 10.1159/000119573. [DOI] [PubMed] [Google Scholar]
  12. Pickering L. K., Ericsson C. D., Ruiz-Palacios G., Blevins J., Miner M. E. Intraventricular and parenteral gentamicin therapy for ventriculitis in children. Am J Dis Child. 1978 May;132(5):480–483. doi: 10.1001/archpedi.1978.02120300040007. [DOI] [PubMed] [Google Scholar]
  13. Schoenbaum S. C., Gardner P., Shillito J. Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy. J Infect Dis. 1975 May;131(5):543–552. doi: 10.1093/infdis/131.5.543. [DOI] [PubMed] [Google Scholar]
  14. Sklaver A. R., Greenman R. L., Hoffman T. A. Amikacin therapy of gram-negative bacteremia and meningitis. Treatment in diseases due to multiple resistant bacilli. Arch Intern Med. 1978 May;138(5):713–716. [PubMed] [Google Scholar]
  15. Strausbaugh L. J., Mandaleris C. D., Sande M. A. Comparison of four aminoglycoside antibiotics in the therapy of experimental E. coli meningitis. J Lab Clin Med. 1977 Apr;89(4):692–701. [PubMed] [Google Scholar]
  16. Swartz M. N. Intraventricular use of aminoglycosides in the treatment of gram-negative bacillary meningitis: conflicting views. J Infect Dis. 1981 Feb;143(2):293–296. doi: 10.1093/infdis/143.2.293. [DOI] [PubMed] [Google Scholar]
  17. Trujillo H., Salgado H., Uribe A., Agudelo N., Zapata C. T., Luisa de Vidal E., Zuluaga A. I. Amikacin concentration in the cerebrospinal fluid of children with acute bacterial meningitis. J Int Med Res. 1979;7(1):45–51. doi: 10.1177/030006057900700107. [DOI] [PubMed] [Google Scholar]
  18. Wright P. F., Kaiser A. B., Bowman C. M., McKee K. T., Jr, Trujillo H., McGee Z. A. The pharmacokinetics and efficacy of an aminoglycoside administered into the cerebral ventricles in neonates: implications for further evaluation of this route of therapy in meningitis. J Infect Dis. 1981 Feb;143(2):141–147. doi: 10.1093/infdis/143.2.141. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES